Navigation Links
Advanced Life Sciences Announces Delisting From Nasdaq and Pending Quotation of its Common Stock on the OTC Bulletin Board

- Company Appeals Delisting Decision to Nasdaq Listing and Hearing Review Council -

CHICAGO, May 4 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS) announced today that the Nasdaq Listing Qualifications Panel (the "Panel") has determined to suspend trading in the Company's common stock from the Nasdaq Stock Market effective at the open of business on Tuesday, May 5, 2009. The Panel's decision was based on the Company's inability to evidence compliance with the $2.5 million shareholders' equity requirement or the $35 million market value of listed securities requirement. The Company requested that the Nasdaq Listing and Hearing Review Council (the "Listing Council") issue a stay on the Panel's decision to suspend the Company's common stock from trading but the Listing Council informed the Company today that it would not call the matter for review. The Company has formally appealed the decision to the Listing Council, which may affirm, modify, reverse, dismiss, or remand the decision.

The Company also announced that it has engaged a market maker that has filed a Form 211 application to quote the Company's common stock on the OTC Bulletin Board (OTCBB). The application is pending with Financial Industry Regulatory Authority (FINRA). Listing on the OTCBB will allow the Company to sell shares of common stock under its Standby Equity Distribution Agreement (SEDA) with YA Global Investments, L.P., an affiliate of Yorkville Advisors, which provides for the sale of up to $15.0 million of shares of the Company's common stock over a two-year commitment period. The Company's common stock will also be eligible for trading on the Pink Sheets beginning on Tuesday, May 5, 2009.

"While we are disappointed by Nasdaq's determination, we will continue to appeal the decision as the OTCBB begins quotation of our securities," stated Dr. Michael T. Flavin, chairman and chief executive officer of Advanced Life Sciences. "The Company has been current in its filings with the SEC and is preparing for a major corporate milestone in our upcoming FDA Advisory Committee meeting scheduled for June 2, 2009 to review the NDA for cethromycin as a treatment for community-acquired pneumonia. As we prepare for that event, we look forward to reestablishing the active market for our shares on the OTC Bulletin Board."

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. For more information, please visit us on the web at

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
3. Advanced Age No Bar to Liver Transplant
4. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
5. Advanced technologies aim to transform the coaching of top athletes
6. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
7. Advanced Life Sciences Joins NASDAQ Capital Market
8. Experimental drug shows promise in advanced kidney cancer
9. TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System
10. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: